10-Q: QuidelOrtho Reports Q2 Loss Amid Restructuring & Revenue Decline

QuidelOrtho Corporation reported a significant net loss in Q2 2025, driven by restructuring charges and a decline in total revenues, despite some growth in core business units.

Summary

• Total revenues for the three months ended June 29, 2025, decreased by 4% to $613.9 million from $637.0 million in the prior year period.
• Total revenues for the six months ended June 29, 2025, decreased by 3% to $1,306.7 million from $1,348.0 million in the prior year period.
• Net loss for the three months ended June 29, 2025, was $255.4 million, compared to a net loss of $147.7 million in the prior year period.
• Net loss for the six months ended June 29, 2025, was $268.1 million, compared to a net loss of $1,853.7 million in the prior year period (which included a $1.7 billion goodwill impairment).
• Restructuring, integration, and other charges significantly increased to $178.9 million for the three months and $195.0 million for the six months ended June 29, 2025, primarily due to the Optimization Plan and Savanna Exit.
• The U.S. donor screening business wind-down contributed to a 61% decrease in Donor Screening revenue for both the three and six months ended June 29, 2025.
• Point of Care revenue decreased by 21% for the three months and 13% for the six months, mainly due to lower sales of QuickVue and Sofia SARS Antigen assays.
• Labs revenue increased by 4% for both periods, driven by growth in reagents, consumables, and services.
• Immunohematology revenue increased by 4% for the three months and 3% for the six months, primarily due to reagent growth.
• Cash and cash equivalents increased to $151.7 million as of June 29, 2025, from $98.3 million at December 29, 2024.
• The company was in compliance with all financial covenants under its Credit Agreement as of June 29, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to increased net losses, declining revenues, significant restructuring charges, and ongoing material weaknesses in internal controls. While there are some positive signs in core business units and liquidity management, the overall financial performance and operational challenges present a cautious outlook.

Positives

• Labs revenue increased by 4% for both the three and six months ended June 29, 2025, indicating strength in core diagnostic areas.
• Immunohematology revenue showed growth of 4% and 3% for the three and six months, respectively, driven by reagent sales.
• Cash and cash equivalents increased by $53.4 million to $151.7 million as of June 29, 2025, improving liquidity.
• The company is in compliance with all financial covenants under its Credit Agreement.
• Cost of sales, excluding amortization of intangible assets, decreased as a percentage of total revenues due to procurement-related cost-savings initiatives.
• Selling, marketing, and administrative expenses decreased by 5.4% for the three months and 7.1% for the six months due to cost-savings initiatives and lower outside services.
• Research and development expense decreased by 18.8% for the three months and 14.4% for the six months, primarily due to cost-savings initiatives.

Negatives

• Total revenues decreased by 4% for the three months and 3% for the six months ended June 29, 2025, compared to prior year periods.
• Net loss significantly increased to $255.4 million for the three months ended June 29, 2025, from $147.7 million in the prior year.
• The company recognized substantial restructuring, integration, and other charges of $178.9 million for the three months and $195.0 million for the six months ended June 29, 2025.
• Donor Screening revenue decreased by 61% due to the planned wind-down of the U.S. donor screening business.
• Point of Care revenue declined by 21% for the three months and 13% for the six months, primarily due to decreased sales of COVID-19 diagnostic tests.
• The company reported material weaknesses in its internal control over financial reporting, which were previously reported and are still being remediated.
• The effective tax rate was negative (11.2% for three months, 12.5% for six months) due to operating losses in certain subsidiaries not being benefited by valuation allowances.
• Working capital, including cash and cash equivalents, decreased to $139.4 million as of June 29, 2025, from $220.1 million at December 29, 2024.

Risks

• Fluctuations in demand for non-respiratory and respiratory products, including COVID-19, flu, strep, and RSV.
• Supply chain, production, logistics, distribution, and labor disruptions and challenges.
• Challenges and costs associated with integrating, restructuring, and achieving anticipated synergies from acquisitions.
• Inability to realize anticipated benefits from discontinuances of business operations (e.g., Savanna Exit) or the Optimization Plan.
• Delays in development or failures/delays in receiving approvals for new or enhanced products.
• Macroeconomic, geopolitical, market, business, competitive, and regulatory factors, including the impact of tariffs and trade policies.
• Highly competitive business environment leading to pricing pressures on certain products.
• Inability to estimate with certainty the costs incurred in product development due to inherent risks.
• Potential material adverse effects from ongoing litigation and other legal proceedings, including class action and derivative lawsuits related to COVID-19 diagnostic tests and Savanna RVP4 assay statements.
• Material weaknesses in internal control over financial reporting could adversely affect the ability to record, process, summarize, and report financial information reliably.

Future Outlook

The company expects overall demand for its non-respiratory and respiratory products to continue fluctuating, with persistent pricing pressures due to increased supply, new variants, and seasonal demands. Long-term growth and profitability depend on retaining and growing customers, attracting new ones through product innovation, and prudently managing the business while introducing new products. The company intends to continue evaluating strategic opportunities to expand product lines, production capabilities, and geographic footprint, and to rationalize facilities to improve long-term results. The Optimization Plan is expected to deliver net cost savings of approximately $50 million through 2027. The wind-down of the U.S. donor screening portfolio is expected to be substantially complete by the first half of 2026, and the Savanna Exit by the first half of 2027.

Management Comments

• Our vision is to advance diagnostics to power a healthier future.
• We aim to support clarity for clinicians and patients to help create better health outcomes.
• We will continue to support our existing customers and honor our contractual commitments during the wind-down of the U.S. donor screening portfolio.
• We continue to monitor our operations for cost-reduction, strategic productivity and margin improvement opportunities to streamline our operations globally and identify additional cost savings.
• We may expand our cost-reduction, strategic productivity and margin improvement initiatives in the future, the costs of which could be material.
• We intend to continue our focus on prudently managing our business and delivering improved financial results, while at the same time striving to introduce new products and services into the market.
• We believe our organizational structure allows us the necessary flexibility to move funds throughout our subsidiaries to meet our operational working capital needs.
• We anticipate that our current Cash and cash equivalents, together with cash provided by operating activities and amounts available under our Revolving Credit Facility, will be sufficient to fund our near-term capital and operating needs for at least the next 12 months.
• We believe that the shift in our sales strategy (reagent rental model) will grow our installed base, thereby increasing sales of higher-margin assays, reagents and other consumables over the life of the customer contracts and enhancing our recurring revenue and cash flows.

Industry Context

The diagnostics industry is experiencing fluctuating demand for respiratory products, particularly post-pandemic, with a decrease in COVID-19 related revenues being partially offset by increases in flu revenues. The sector is highly competitive, leading to pricing pressures. Companies are focusing on cost-reduction initiatives and strategic portfolio adjustments (like the wind-down of lower-margin businesses and investment in new platforms) to adapt to changing market dynamics and improve long-term profitability. Geopolitical tensions and tariffs are also noted as potential macroeconomic challenges impacting global supply chains and costs.

Corporate Governance

Legal Proceedings

• A putative class action complaint, Bristol County Retirement System v. QuidelOrtho Corporation, et al., filed on April 12, 2024, asserting claims for violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 related to statements regarding COVID-19 diagnostic tests and Savanna RVP4 assay submission. Lead plaintiffs filed an amended complaint on February 7, 2025, and defendants filed a motion to dismiss on April 4, 2025.
• Two stockholder derivative complaints, Matthew Whitfield v. Kenneth F. Buechler, Ph.D., et al. (filed April 25, 2024) and Steven Pinkney v. Douglas Bryant, et al. (filed June 21, 2024), consolidated into a single action, asserting claims for violations of Sections 10(b), 14(a), and 20(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets related to similar statements. The consolidated derivative action was stayed on December 16, 2024.
• The company disputes the allegations and intends to defend itself vigorously. It is unable to estimate a possible loss or range of loss from these lawsuits or determine if such loss would have a material adverse effect, though management believes current legal actions in aggregate are not expected to have a material adverse effect.

Related Party Transactions

• The company has an ongoing Joint Business with Grifols relating to Ortho's Hepatitis and HIV diagnostics business. The company's portion of the pre-tax net profit shared under this Joint Business was $5.0 million for the three months and $20.9 million for the six months ended June 29, 2025.

Stakeholder Impact

• Shareholders: Impacted by significant net losses, declining revenues, and ongoing legal proceedings, which could negatively affect share price and equity value. The company's strategic shifts and cost-saving initiatives aim for long-term value creation.
• Employees: Affected by restructuring and cost-reduction initiatives, including workforce reductions, as part of the Optimization Plan and Savanna Exit.
• Customers: The wind-down of the U.S. donor screening portfolio will require transition for affected customers, though the company plans to honor contractual commitments. The reagent rental model aims to lower upfront costs for customers and expand market reach.
• Creditors: The company remains in compliance with financial covenants, indicating continued ability to service debt, but increased current portion of borrowings and overall liabilities warrant monitoring.
• Suppliers: Procurement-related cost-savings initiatives may impact supplier relationships and pricing.

Next Steps

• Continue implementation of cost-reduction, strategic productivity, and margin improvement initiatives under the Optimization Plan through 2027.
• Substantially complete the wind-down of the U.S. donor screening portfolio by the first half of 2026.
• Substantially complete the discontinuation of the Savanna platform by the first half of 2027.
• Continue to evaluate strategic opportunities to expand product lines, services, production capabilities, technologies, and geographic footprint.
• Continue to rationalize and consolidate facilities to improve long-term results.
• Continue to implement ERP systems in phases over the next several years.
• Continue to assess the impact of ERP implementation on internal control over financial reporting.
• Remediate material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company is undergoing significant strategic shifts, including a major restructuring plan and the discontinuation of a key platform (Savanna), which are incurring substantial short-term costs and contributing to current losses. While these actions are intended to drive long-term efficiency and profitability, the immediate financial results show declining revenues and increased net losses. The presence of material weaknesses in internal controls and ongoing legal proceedings add to the uncertainty. However, the company's liquidity position appears stable, and it remains in compliance with debt covenants. The growth in Labs and Immunohematology segments offers a glimmer of strength in core areas. Given the current transitional phase, the high costs of restructuring, and the legal/governance issues, a 'hold' recommendation is appropriate. Investors should await clearer signs of successful execution of the Optimization Plan and resolution of legal/control issues before considering a 'buy', while the core business strength and strategic intent prevent a 'sell'.

Keywords

Diagnostics, Medical Devices, In Vitro Diagnostics, Molecular Diagnostics, Immunohematology, Point of Care, Labs, COVID-19, Respiratory Diagnostics, SEC Filing, Financial Results, Restructuring, Cost Savings, Goodwill Impairment, Legal Proceedings